Medtronic (NYSE:MDT) Stock Price Expected to Rise, Robert W. Baird Analyst Says

Medtronic (NYSE:MDT) had its target price upped by analysts at Robert W. Baird from $92.00 to $93.00 in a research note issued to investors on Wednesday,MarketScreener reports. The brokerage currently has a “neutral” rating on the medical technology company’s stock. Robert W. Baird’s price objective points to a potential upside of 8.57% from the stock’s previous close.

MDT has been the subject of a number of other reports. CICC Research began coverage on shares of Medtronic in a research report on Friday, January 30th. They set an “outperform” rating for the company. Citigroup dropped their price target on shares of Medtronic from $117.00 to $110.00 and set a “buy” rating for the company in a research report on Tuesday, April 7th. Truist Financial dropped their price target on shares of Medtronic from $107.00 to $103.00 and set a “hold” rating for the company in a research report on Wednesday, February 18th. Stifel Nicolaus dropped their price target on shares of Medtronic from $105.00 to $95.00 and set a “hold” rating for the company in a research report on Monday, April 6th. Finally, Piper Sandler dropped their price objective on shares of Medtronic from $105.00 to $91.00 and set a “neutral” rating for the company in a report on Wednesday, April 1st. Sixteen analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat, Medtronic currently has a consensus rating of “Moderate Buy” and a consensus price target of $109.25.

Medtronic Price Performance

Shares of MDT stock opened at $85.66 on Wednesday. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.54 and a quick ratio of 1.87. The firm’s 50-day moving average is $91.85 and its two-hundred day moving average is $95.75. Medtronic has a 12 month low of $79.93 and a 12 month high of $106.33. The company has a market capitalization of $109.98 billion, a PE ratio of 23.86, a price-to-earnings-growth ratio of 2.26 and a beta of 0.75.

Medtronic (NYSE:MDT) last announced its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, beating analysts’ consensus estimates of $1.34 by $0.02. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The business had revenue of $9.02 billion during the quarter, compared to analysts’ expectations of $8.89 billion. During the same period last year, the business earned $1.38 earnings per share. The business’s revenue for the quarter was up 5.8% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Analysts predict that Medtronic will post 5.46 earnings per share for the current year.

Insiders Place Their Bets

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the company’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the sale, the executive vice president owned 32,768 shares in the company, valued at $3,201,761.28. This represents a 61.58% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.26% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Monetary Solutions Ltd acquired a new position in Medtronic during the 4th quarter worth approximately $27,000. Corundum Trust Company INC acquired a new position in Medtronic during the 3rd quarter worth approximately $27,000. Lodestone Wealth Management LLC acquired a new position in Medtronic during the 4th quarter worth approximately $27,000. Anfield Capital Management LLC grew its holdings in Medtronic by 410.7% during the 4th quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 230 shares in the last quarter. Finally, Board of the Pension Protection Fund acquired a new position in Medtronic during the 4th quarter worth approximately $29,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).